Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy – Market Realist
|
Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy
Market Realist In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy that includes SB-525, which is one of Sangamo Therapeutics' four lead product candidates. This collaboration is highly synergistic, as it … Zacks Premium Investment Service – Zacks.com Sangamo Therapeutics, Inc. – SGMO – Stock Price Today – Zacks |
